Cross-reactive probes on Illumina DNA methylation arrays: a large study on ALS shows that a cautionary approach is warranted in interpreting epigenome-wide association studies by Hop, P.J. et al.
This is a repository copy of Cross-reactive probes on Illumina DNA methylation arrays: a 
large study on ALS shows that a cautionary approach is warranted in interpreting 
epigenome-wide association studies.




Hop, P.J., Zwamborn, R.A.J., Hannon, E.J. et al. (17 more authors) (2020) Cross-reactive 
probes on Illumina DNA methylation arrays: a large study on ALS shows that a cautionary 
approach is warranted in interpreting epigenome-wide association studies. NAR Genomics





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Published online 17 December 2020 NAR Genomics and Bioinformatics, 2020, Vol. 2, No. 4 1
doi: 10.1093/nargab/lqaa105
Cross-reactive probes on Illumina DNA methylation
arrays: a large study on ALS shows that a cautionary
approach is warranted in interpreting epigenome-wide
association studies
Paul J. Hop 1, Ramona A.J. Zwamborn1, Eilis J. Hannon 2, Annelot M. Dekker1,
Kristel R. van Eijk1, Emma M. Walker2, Alfredo Iacoangeli 3,4, Ashley R. Jones3,
Aleksey Shatunov3, Ahmad Al Khleifat3, Sarah Opie-Martin3, Christopher E. Shaw3,5,
Karen E. Morrison6, Pamela J. Shaw7, Russell L. McLaughlin 8, Orla Hardiman9,10,
Ammar Al-Chalabi3,11, Leonard H. Van Den Berg1, Jonathan Mill2 and Jan H. Veldink1,*
1Department of Neurology, UMC Utrecht Brain Center, 3584 CG, Utrecht, the Netherlands, 2University of Exeter
Medical School, University of Exeter, Exeter EX2 5DW, UK, 3Department of Basic and Clinical Neuroscience, King’s
College London, Maurice Wohl Clinical Neuroscience Institute, London SE5 9RS, UK, 4Department of Biostatistics
and Health Informatics, King’s College London, London SE5 8AF, UK, 5UK Dementia Research Institute, King’s
College London, London WC2R 2LS, UK, 6Faculty of Medicine, Health & Life Sciences, Queen’s University Belfast,
90 Lisburn Road, Belfast, BT9 6AG, Northern Ireland, UK, 7Sheffield Institute for Translational Neuroscience,
University of Sheffield, Sheffield S10 2HQ, UK, 8Complex Trait Genomics Laboratory, Smurfit Institute of Genetics,
Trinity College Dublin, Dublin D02 DK07, Republic of Ireland, 9Academic Unit of Neurology, Trinity College Dublin,
Trinity Biomedical Sciences Institute, Dublin D02 PN40, Republic of Ireland, 10Department of Neurology, Beaumont
Hospital, Dublin D02 PN40, Republic of Ireland and 11Department of Neurology, King’s College Hospital, Bessemer
Road, London, SE5 9RX, UK
Received May 06, 2020; Revised October 27, 2020; Editorial Decision November 23, 2020; Accepted November 25, 2020
ABSTRACT
Illumina DNA methylation arrays are a widely used
tool for performing genome-wide DNA methylation
analyses. However, measurements obtained from
these arrays may be affected by technical artefacts
that result in spurious associations if left unchecked.
Cross-reactivity represents one of the major chal-
lenges, meaning that probes may map to multiple
regions in the genome. Although several studies
have reported on this issue, few studies have empir-
ically examined the impact of cross-reactivity in an
epigenome-wide association study (EWAS). In this
paper, we report on cross-reactivity issues that we
discovered in a large EWAS on the presence of the
C9orf72 repeat expansion in ALS patients. Specifi-
cally, we found that that the majority of the significant
probes inadvertently cross-hybridized to the C9orf72
locus. Importantly, these probes were not flagged as
cross-reactive in previous studies, leading to novel
insights into the extent to which cross-reactivity can
impact EWAS. Our findings are particularly relevant
for epigenetic studies into diseases associated with
repeat expansions and other types of structural vari-
ation. More generally however, considering that most
spurious associations were not excluded based on
pre-defined sets of cross-reactive probes, we believe
that the presented data-driven flag and consider ap-
proach is relevant for any type of EWAS.
INTRODUCTION
DNA methylation is a key epigenetic mechanism that is in-
volved in gene regulation by influencing transcription fac-
tor binding and recruiting histone-modifying proteins (1). It
involves the addition of a methyl group to the DNA, which
occurs predominantly at CpGdinucleotides.DNAmethyla-
tion patterns are propagated through cell division and play
a key role in development, where it is involved in tissue-
specific transcriptional regulation and genomic stability (2).
DNAmethylation at certain loci remains dynamic through-
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out life and can be influenced by the environment, lifestyle
and ageing (3). Importantly, aberrations in DNA methyla-
tion patterns have been associated with a wide range of hu-
man diseases including cancer, cardiovascular disease and
schizophrenia (3–5).
An important driver in expanding our understanding of
DNA methylation in health and disease has been the grow-
ing number of epigenome-wide association studies (EWAS)
(6). These studies were facilitated by the advance of high-
throughput techniques that quantify DNA methylation at
sites across the genome. Among these techniques, the Il-
lumina Infinium BeadChip arrays have been used most
widely, offering genome-wide coverage at a relatively low
cost (7). There are several generations of Illumina methy-
lation beadchips available (27K, 450K and EPIC array, re-
spectively), which all use similar probe-based technology,
but newer generations see increased coverage. The Infinium
methylation technology is based on bisulfite treatment of
DNA, which converts all unmethylated Cs into Ts, thereby
introducing a C/T genetic variant in CpG-sites that can be
interrogated using microarray technology.
Although several studies have shown that these arrays
generally provide accurate and reproduciblemeasures, there
have been various reports on technical artefacts that can re-
sult in spurious results (8–12). Cross-reactivity presents one
of the major technical artefacts, where probes may map to
multiple locations in the genome and therefore measure a
mixture of specific and aspecific signals. In the first report
on cross-reactivity in Illumina DNAmethylation arrays the
authors showed thatmany sex-associated autosomal probes
on the 27K array were caused by cross-hybridization to
the sex chromosomes (13). Since then, several studies have
reported on cross-reactive probes in both the 450k and
EPIC array, resulting in a variety of probes that should
be excluded (9–12). More often than not, this concerns a
substantial number of probes (ranging from 6 to 11% of
all probes). However, despite these comprehensive efforts,
there is still a lack of studies showing the actual impact of
cross-hybridization in EWAS.
Here, we report on unreported issues of cross-reactivity
that we discovered while pursuing EWAS in large cohorts
of patients with amyotrophic lateral sclerosis (ALS) and
controls. Specifically, we focused on the identification of
DNA methylation profiles associated with the presence of
the C9orf72 (C9) repeat expansion, a GGGGCC (G4C2)
nucleotide repeat expansion, which is the most common
mutation (±8%) in both ALS and frontotemporal demen-
tia (14). We provide compelling evidence that the majority
of the loci that were associated with the presence of the C9
repeat expansion result from cross-hybridiziation to the re-
peat sequence. Importantly, these issues affected the major-
ity of the significant results, and the spurious associations
were not excluded based on sets of cross-reactive probes es-
tablished in previous studies. In this paper we show that:
(i) limited (≤30 bp) off-target sequence matches can re-
sult in cross-hybridization in Illumina Methylation arrays,
which is below the criteria used in previous research; (ii)
imperfect matches (i.e. with mismatches/INDELs) to off-
target regions can result in spurious associations; and (iii)
genetic variation (especially tandem repeats and other types
of structural variation) associated with the phenotype of in-
terest could severely confound EWAS analyses because they
are not included in existing annotations of cross-reactive
probes that are based on the reference genome.
We show that these issues apply to both the most re-
cent EPIC array as well as the older, but more widely used,
450k array. Our findings serve as a cautionary note to re-
searchers using Illumina arrays, and we provide several rec-




All ALS patients included in this study were collected as
cohorts in ProjectMinE (www.projectmine.com), described
in more detail elsewhere (15).
NL. All participants gave written informed consent and
approval was obtained from the local, relevant IRB com-
mittees for medical research. DNA methylation profiling
was performed on 2916 samples, comprising 1867 patients
with ALS and 1049 controls. All patients were diagnosed
according to the revised El Escorial criteria. Control sub-
jects were from ongoing population-based studies on risk
factors in ALS.
UK. Cases were diagnosed with probable or definite ALS
according to the 1994 El Escorial Criteria by neurologists
specialized in motor neuron diseases. Control samples were
collected from neurologically normal, unrelated individu-
als, either spouses of ALS patients, carers or blood donors
from the same geographical region. DNA methylation pro-
filing was performed on 383 samples, comprising 266 pa-
tients with ALS and 117 controls.
Ireland. Cases were diagnosed with probable or definite
ALS according to the 1994 El Escorial Criteria by neu-
rologists specialized in motor neuron diseases Beaumont
Hospital in Dublin. Patients were referred from all regions
in Ireland and were part of an ongoing population-based
prospectiveALS registry. Control samples werematched for
gender and age. They were either spouses or those accom-
panying patients to the ALS clinic. All individuals reported
Irish ancestry for at least three generations. DNA methy-
lation profiling was performed on 298 samples, comprising
200 patients with ALS and 98 controls.
DNA methylation profiling
Venous blood was drawn from patients and controls from
which genomic DNA was isolated using standard methods.
We set the DNA concentrations at 100 ng/l as measured
by a fluorometer with the PicoGreen®; dsDNA quanti-
tation assay. DNA integrity was assessed using gel elec-
trophoresis. Genomic DNA (∼1g) was bisulfite-treated
using Zymo Bisulfite Conversion Kits (ZymoResearch, Or-
ange, CA, USA). DNA methylation was analyzed using
the Infinium Methylation450k array (NL samples) or In-
finium EPIC array (UK and Ireland samples), according to
the standard Infinium HD array methylation protocol (Il-
lumina, San Diego, CA, USA)
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Software & Availability
For EWAS analyses we used the OSCA software v0.41
(available at: http://cnsgenomics.com/software/osca) (16).
All other analyses were performed in the statistical pro-
gramming language R (version 3.5) (17). Figures weremade
with the R package ggplot2, using the colorblind-friendly
color palette published by Ichihara et al. (18,19). Figure
2A was made using the pheatmap package (20). Probe map-
ping was performed using the Biostrings package (21). Fi-
nally, several other packages were used, mostly from the
tidyverse (22), for a complete overview of packages see the
github page below. All code is available at https://github.
com/pjhop/dnamarray crossreactivity which includes doc-
umentation on the data scructure and scripts used. Fur-
thermore, we made several main functions are available
as an installable R package at: https://github.com/pjhop/
DNAmCrosshyb.
Quality control & normalization
Raw signal intensities were read intoR using theminfi pack-
age (23).
Sample QC. We performed quality control and normal-
ization separately for the 450k data (NL) and EPIC data
(UK and Ireland). Identical thresholds were used for 450k
and EPIC data, unless indicated. Samples that failed the
following criteria were removed: (i) Samples with median
methylated or unmethylated intensity <1500 (<2000 for
EPIC data). (ii) Samples with median red/green ratio <0.5
or >2 as calculated in type I probes (<0.4 or >2.5 in EPIC
data). (iii) Discordance between reported sex and predicted
sex based on the getSex function in minfi (23). (iv) Sam-
ples that failed on the OP (non-polymorphic controls) or
Hyb (hybridization controls) metrics as implemented in the
methylaid package (24). (v) Samples with incomplete bisul-
fite conversion (<80%) based on the bsconmetric as imple-
mented in thewateRmelon package (25). (vi) Samples where
>5% of probes had detection P-value < 1 × 10−16 and/or
>5% of probes were measured by <3 beads. (vii) Sam-
ples that failed on the inbreeding and relatedness metrics in
the corresponding whole-genome-sequencing (WGS) data.
Quality control of the Project MinE WGS data was per-
formed as described earlier (15). (viii) We removed samples
that did not match their respective genotype data. Briefly,
we used the omicsPrint package to select 200 probes that
reliably measured underlying SNPs and were present in
the WGS-derived SNP data (26). We performed identity-
by-state (IBS) between the DNAm-inferred SNPs and the
WGS-derived SNPdata using the allelesharing function.We
removed samples for which the DNAm-inferred SNPs did
not match the WGS-derived SNPs (IBS mean <1.9 and/or
IBS variance >0.1). Finally, we removed one individual for
each related pair of individuals (identical or first-degree) to
obtain a set of unrelated individuals. The number of sam-
ples that failed on the various QC metrics are listed in Sup-
plementary Tables S1 and 2. The baseline characteristics for
samples that pass QC are provided in Supplementary Tables
S3 and 4.
Probe QC. We first removed samples that failed QC and
then set all the measurements with detection P-value > 1
× 10−16 or measured by <3 beads to missing (27). We then
removed all probes with >5% missing data.
Normalization. The QC’ed signal intensities were normal-
ized using the dasen function as implemented in the wateR-
melon package (25). For type I probes, we also extracted
the out-of-band (OOB) signal intensities (28) (see next sec-
tion). The OOB signal intensities were normalized using the
naten function as implemented in the wateRmelon package
(25). Note that naten performs the same normalization pro-
cedure as dasen, except that it does not equalize type I and
type II backgrounds (which is not relevant for OOB inten-
sities, since these exist only for type I probes).
Out-of-band (OOB) signal
Color channel switches can occur in type I probes, where
signals from both the methylated and unmethylated beads
are measured in the same designated color channel. The un-
used color channel is termed the OOB channel. If a probe
hybridizes to an off-target region, the base preceding the
off-target CpG-site may be different than the base preced-
ing the intended CpG-site. If so, this can result in the incor-
poration of a differently labeled nucleotide, in which case
signal from the off-target region would be measured in the
OOB color channel.
Calculation of in-band and OOB -values
We transformed the normalized signal intensities into -





Here, M represents methylated intensity and U represents
unmethylated intensity. We used the same formula for in-
band and OOB signal intensities.
Phenotypes
C9orf72 expansion status was determined using the Illu-
mina ExpansionHunter tool where subjects with ≥30 re-
peats were classified as carriers of the repeat expansion
(29,30). Since chronological age, smoking status and white
blood cell (WBC) fractions were not available for all sam-
ples, we used established prediction algorithms to impute
them. Age was predicted using the agep function in the wa-
teRmelon package, which uses the coefficients from Hor-
vath’s multi-tissue age predictor (25,31). We calculated a
smoking score as previously described inElliot et al. and im-
plemented in the EpiSmoker package (32,33). We imputed
white blood cell fractions (CD8T cells, CD4T cells, Mono-
cytes, Granulocytes, B cells andNK cells) using theEpiDish
package, where we used the ‘RPC’ (Robust Partial Correla-
tions) algorithm (34). Since the WBC fractions always add
up to one, we dropped one cell-type (B-cells) in the analyses
to prevent multicollinearity among the WBC covariates.
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EWAS on C9orf72 expansion status
Weperformed anEWASofC9orf72 expansion statuswithin
ALS cases using a mixed linear model as implemented in
the OSCA software (16). Briefly, this algorithm tests for an
association between the methylation status of a CpG-site
(-value) and a trait (in this case C9orf72 status) while fit-
ting all the other distal probes as random effects. Fitting the
distal probes as random effects accounts for correlations in-
duced by (unobserved) confounding factors. Specifically, we
used the ‘LOCO’ option, which excludes all probes located
on the same chromosome as the target site from the random
effects terms so that the target site is not fitted twice (once
as a fixed effect and once as a random effect). We included
sex, experimental batch, predicted age and predicted smok-
ing score as fixed covariates in the model.
We used the same algorithms as described above for the
EWASs on OOB -values and EWASs on total signal in-
tensities. In case the OSCA algorithm did not converge, we
used a multivariate linear model adjusting for experimental
batch, age, sex, smoking score, imputed cell fractions, the
first five array-wide PCs and the first five control probe PCs.
This was the case for the EWAS on total signal intensities
and the EWAS in the EPIC replication dataset.
Identification of probes that (partially) map to the C9 repeat
We generated the forward and reverse strand of the
GGGGCC hexanucleotide repeat in silico. Although the
number of repeats differs per carrier, we used a fixed num-
ber of 10 repeats (60 bp), which is sufficient for the full 50-nt
sequence of a probe to match. Both strands were bisulfite-
converted in silico, where all non-CpG cytosines were con-
verted in T’s and C’s in CpG-sites were either converted to
Ts (unmethylated) or Cs (methylated). We then generated
the complement strands of the bisulfite-converted strands,
resulting in four strands in total (forward, reverse, forward
complement and reverse complement).
We downloaded the Illumina 450k andEPIC annotations
as implemented in Bioconductor (35). The probe sequences
for type I probes were directly extracted from the annota-
tion files, consisting of two probe sequences per CpG-site
(methylated + unmethylated). Type II probes contain up to
three R bases (R = A or G in IUPAC code) in the probe
sequence, resulting in up to 8 (23) possible probe sequences
per CpG-site. We generated all possible combinations for
the type II probes and combined them with the type I probe
sequences, resulting in 1 119 157 450k probe sequences and
1 752 933 EPIC probe sequences.
For each width between 1 and 50 bp we scanned the 3′-
subsequence of the probe’s sequence for overlap with the
four bisulfite-converted hexanucleotide repeat strands using
theBiostrings package inR (21).We repeated this procedure
for several scenarios:
(i) Assuming that the repeat is either fully methylated (all
C’s of CpGs remain C’s), or that the repeat is fully un-
methylated (all C’s of CpGs are converted into T’s).
(ii) Allowing every combination of DNA methylation
states within the repeat by converting all C’s of CpGs
to Y’s (Y = T or C in IUPAC code).
(iii) Allowing a mismatch or an INDEL >5 bp of the 3′end
of the probe sequence. The 5 bp cutoff is based on the
finding by Zhou et al. that variation nearer to the 3′ site
of the probe will not result in hybridization (12).
RESULTS
EWAS on C9orf72 status identifies 18 genome-wide signifi-
cant loci
After stringent quality control, we performed an EWAS
of C9orf72 (C9) repeat expansion status (wild-type or ex-
panded) within 1748 ALS patients (see Supplementary Ta-
bles S1–3 for an overview of QC steps and study popula-
tion). We tested for an association between DNA methy-
lation at 467 303 sites (450k array) and C9 status, using
mixed linear models where all distal probes were fitted as
random effects as implemented in the OSCA software (16).
Specifically, we used the LOCO (leave-one-chromosome-
out) option to prevent the same probe being fitted twice and
included age, sex, smoking score and experimental batch
as fixed covariates. We observed modest deflation of test-
statistics in the quantile–quantile plot (λ = 0.946, Figure
1B), and sensitivity analyses indicated that the results were
robust to changes in analysis strategy (Supplementary Fig-
ure S1). We identified 18 sites at which DNA methyla-
tion was significantly associated with the presence of the
C9 repeat expansion at a Bonferroni-corrected significance
threshold (P < 1.1 × 10−7, Figure 1B; Supplementary Ta-
ble S10). Six of the significant CpG-sites were located in cis
of the C9 repeat (<100 kb), with four of these located in a
CpG island directly upstream of the repeat. The remaining
12 CpGs were located in trans of the C9 repeat expansion,
being distributed across chromosomes (Figure 1A). All sig-
nificant trans sites showed increased DNAmethylation lev-
els in C9 carriers.
Significant transCpG-sites exhibit ambiguous characteristics
Although the identified trans CpG-sites initially seemed in-
teresting, several observations led us to suspect that these
associations actually reflected technical artefacts. First, we
observed notable correlations in DNA methylation levels
across the majority of trans CpG-sites (Figure 2A), sug-
gesting that a common factor underlies these associations.
Although this might reflect a coordinated DNA methyla-
tion signal, it might also indicate that a common techni-
cal or biological confounder is influencing DNA methyla-
tion levels across sites (16). Second, closer inspection of
the trans loci showed that the associations did not ex-
tend to the regions surrounding the trans CpG-sites (Fig-
ure 2B and Supplementary Figure S2). Importantly, tech-
nical artefacts are more likely to affect single CpGs (36).
Inspection of the specific probe sequences revealed that
11 (92%) of the trans probes share a similar 3′ sequence
(Supplementary Table S5), with the 3′-ends of these probes
showing homology to the bisulfite-converted C9 repeat
expansion (note that each repeat contains one CpG-site,
Figure 2C).
Together, these observations suggest that the identified
trans associations do not reflect true DNAmethylation dif-
NAR Genomics and Bioinformatics, 2020, Vol. 2, No. 4 5
Figure 1. EWAS on C9 status within ALS patients. (A) Manhattan plot comparing association P-values (−log10(P), y-axis) and genomic location (x-
axis). The dashed line indicates the bonferroni significance threshold (1.1 × 10−7). (B) QQ-plot showing observed P-values (−log10(P), y-axis) against the































































































































































































































































Figure 2. (A) Heatmap showing the correlations between the 18 CpGs that were significantly associated with C9 status. Correlations were calculated within
carriers of the C9 expansion. Probes are annotated with their respective positions: the upper cluster consists of 10 probes in trans (>100 kb) of the C9
repeat, the middle cluster consists of four probes located in the CpG island upstream of the repeat, and the lower cluster consists of two trans probes and
two cis probes. (B) Locus plots of the two most significant trans CpGs. There are no regional effects in the trans associations. Locus plots for all trans
probes are shown in Supplementary Figure S2. (C) Example of the C9 GGCCCC hexanucleotide repeat after bisulfite conversion (forward strand shown),
where we assumed that the repeat is fully methylated (43). The probe sequence of one of the trans CpG-sites (cg01587390) is displayed, showing that the 3′
end of the probe partially matches the bisulfite-converted C9 repeat.
ferences at the intended regions, but instead reflect differ-
ential DNA methylation at the C9 repeat due to cross-
hybridization. Since the size of the C9 expansion ranges
from hundreds to thousands of repeats, a sequencematch to
the repeat sequence could lead tomany off-target hybridiza-
tion events in carriers of the mutation. This would in turn
lead to an increased signal intensity for these probes, and
importantly, could lead to shifts in -values resulting in dif-
ferential methylation readouts.
In the following sections we provide a more detailed ex-
amination of this issue, leading to novel insights regarding
cross-hybridization in Illumina methylation arrays.
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Figure 3. Comparison between P-values from the C9orf72 EWAS and match (bp) between the probe’s 3′-subsequence and the bisulfite-converted C9orf72
repeat (see Supplementary Figure S4 for type II probes). Here, we assumed that the repeat was completely methylated (i.e. all Cs converted to Ts, except
C’s in CpG-sites). (A) Comparison between P-values from the C9 EWAS and match (bp) between the probe’s 3′-subsequence and the bisulfite-converted
C9 repeat. (B) Comparison between the P-values (−log10(P), y-axis) from the C9 EWAS and match between the probe’s 3
′-subsequence. P-values from
the EWAS on OOB -values were used in case of a predicted color channel switch (OOB probes). (C) Comparison between the length of the inexact
match to the C9 repeat (y-axis) and exact match to the C9 repeat for type I probe sequences. Points are colored by significance levels in the C9 EWAS.
(D) Comparison between the P-values (−log10(P), y-axis) from the C9 EWAS and inexact match between the probe’s 3
′-subsequence. P-values from the
EWAS on OOB -values were used in case of a predicted color channel switch (OOB probes).
Identification of probes that map to the C9 repeat
To determine the extent of probes that (partially) match the
C9 repeat, we mapped all probes on the 450k array (485 512
probes) to the bisulfite-converted C9 repeat sequence in sil-
ico. Briefly, for each width between 1 and 50 bp we scanned
the 3′-subsequence of the probe sequence for a match with
the four bisulfite-converted hexanucleotide repeat strands.
We first focused on type I probes (since all suspicious trans
probes were this bead type) and assumed that the repeat was
fully methylated (all CpGs in the repeat are assumed to be
methylated, Figure 2C).
As Figure 3 A shows, several significant trans probes par-
tially match (≥14 bp) the C9 repeat, while none of the probe
sequences of the significant cis associations match the re-
peat (note that we used cutoff of ≥14 bp to define probes
that partially match to the C9 repeat, we will consider this
cutoff in more detail later). We found however that, some
probes that partially match to the C9 repeat failed to reach
significance in the EWAS. Moreover, we note that several
genome-wide significant trans probes had only a limited
match to the C9 repeat (>5 bp, <14 bp). We discovered
that these observations could be explained by color chan-
nel switches and imperfect matches respectively, which we
discuss in more detail in the following section.
Color channel switches. We hypothesized that the lack of
association of some of the trans probes that do partially
match the C9 repeat could be explained by color channel
switches (4 out of 10 probes with a ≥14 bp C9 match were
not significant). To investigate this hypothesis we first pre-
dicted for each probe whether a color-channel switch would
occur if the probe would hybridize to the C9 repeat (seeMa-
terials and Methods section). For probes with an expected
color-channel switch upon C9 hybridization (dubbed ’OOB
probes’), we expect differential signal in the OOB color
channels. We therefore performed an EWAS using -values
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Table 1. Number of significant sites in the EWAS and the OOB that were identified as mapping to the C9 repeat
Annotated location






EWAS cis 6 0 (0%) 0 (0%)
trans 12 11 (92%) 11 (92%)
OOB EWAS cis 0 0 (0%) 0 (0%)
trans 9 8 (89%) 9 (100%)
*Defined as an ≥14 bp inexact match to the C9 repeat (allowing one mismatch/INDEL >5 bp from the 3′-end of the probe).
**See Supplementary text and Supplementary Figures S10–15. One significant OOB site was classified as C9-mapping when allowing mismatch/INDELS
closer to the 3′-end of the probe.
calculated from the OOB channels (dubbed OOB EWAS,
Supplementary Figure S3). Nine probes were significant in
the OOB EWAS, of which six were were predicted to result
in OOB signal upon hybridization to the C9 repeat (OOB
probes). The remaining 3 sites were significant in both the
original EWAS and the OOB EWAS.
In Figure 3B we highlight the OOB probes and updated
the P-values of these probes with P-values from the OOB
EWAS (Supplementary Figure S3). Strikingly, the OOB
probes with a ≥14 bp match that were not significant in the
original EWAS (three probes), were highly significant in the
OOB EWAS. In total, using -values calculated in the pre-
dicted color channels, 9 out of 10 type I probeswith a≥14bp
C9 match were significantly associated with C9 status.
Inexact matching. We hypothesized that the significant
trans probes with a limited C9 repeat match (six in-band
probes and three OOB probes) may match imperfectly
(i.e. with mismatches and/or gaps). We therefore reran the
mapping procedure using inexact matching where we al-
lowed one mismatch/INDEL. We excluded matches with
a mismatch/INDEL near the 3′-end of the probe (≤5 bp)
since it has been previously shown that these prevent hy-
bridization (12). Several probes showed a markedly in-
creased match length when inexact matching was applied
(Figure 3C). Seven out of the nine significant trans probes
with a <14 bp exact C9 match had an ≥14 bp inexact C9
match. This suggests that an inexact match between a probe
and the DNA sequence can lead to sufficient off-target hy-
bridization to result in spurious associations.
We repeated the above analyses for type II probes, find-
ing that relatively fewer type II probes partially match the
C9 repeat: one probe had an exact match of ≥14 bp, and
this number increased to 30 probes when applying inexact
matching (Supplementary Figure S4). There were no signif-
icant associations among these probes.
Majority of results are affected by previously unidentified
cross-hybridization issues
Enrichment of C9-mapping probes. In total, we identified
137 probes with an ≥14 bp inexact match to the C9 repeat
(dubbed the C9-mapping probes). These include the major-
ity of the sites that were significantly associated with C9 sta-
tus (11 out of 18, Supplementary Figure S5A), representing
a strong enrichment (OR = 5288, P=1.9 × 10−35, Table 1).
We further found that eight out of the nine significant sites
identified in the OOB EWAS were among the C9-mapping
probes (Supplementary Figure S5B and Table 1), provid-
ing strong evidence that cross-hybridization can lead to de-
tectable OOB signal.
We do note that the chosen 14 bp cutoff used to define
C9-mapping probes is data-driven and could therefore be
biased (the cutoff was based on the observation that most
significant trans probes had a ≥14 bp match to the C9 re-
peat). However, we found that for a range of cut-offs, the
significant probes from the C9 EWAS were strongly en-
riched for probes with longermatches to theC9 repeat (Sup-
plementary Figure S6). We note that we made several as-
sumptions in matching the probes with the C9 repeat ex-
pansion. We therefore performed several sensitivity analy-
ses that showed that different assumptions have little im-
pact on the results (see Supplementary Figure S10 and the
Supplementary text). We did find, however, that allowing
a mismatch/INDEL at any position in the probe (instead
of >5bp from the 3′-end) led to an additional significant
OOB probe being classified as C9-mapping (≥14 bp C9
match), resulting in all 9 significant OOB probes being clas-
sified as C9-mapping (Table 1). This indicates that off-target
matches with a mismatch close to the 3′-end of the probe
may still result in cross-hybridization. Finally, we assessed
whether the identified associations were driven by outliers,
which could indicate that a few carriers with very large re-
peat expansions drive the results. We found however, that
there were marked differences in median -values for both
the in-band and OOB C9-mapping probes (Supplementary
Figures S8 and 9), suggesting that the identified associations
were not driven by outliers.
Evaluation of existing methods. Previous studies on cross-
hybridization have reported varying numbers of probes that
may hybridize to multiple locations in the genome (10–12).
However, we found that few to none of the cross-hybridizing
probes identified in this study were flagged as such in previ-
ous studies (Supplementary Table S6). Moreover, we eval-
uated several methods designed to adjust for hidden con-
founders in EWAS studies and found that, regardless of the
method used, 40–60% of significant results were affected
by cross-hybridization (Supplementary Table S7) (16,37–
39). Together, these findings suggest that existing meth-
ods to account for bad quality probes and confounding
may not suffice in preventing spurious results due to cross-
hybridization.
C9-mapping probes show significant differences in signal in-
tensity
To further substantiate that the observed findings are
caused by cross-hybridization, we evaluated the total sig-
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Figure 4. Comparison between association test-statistics between C9 status and total signal intensities (y-axis) and association test-statistics between C9
status and -values. (A) In-band test-statistics. Probes flagged as mapping to the C9 repeat (≥14 bp inexact match) and that were significant in the EWAS
are highlighted (fourth column in Table 1). (B) OOB test-statistics. Probes flagged as mapping to the C9 repeat (≥14 bp inexact match) and that were
significant in the OOB EWAS are highlighted (fourth column in Table 1).
nal intensities at these sites. For probes that map to the C9
repeat, we expect more hybridization events in carriers of
the repeat expansion, which would in turn lead to an in-
creased total signal intensity. To test this, we tested for an
association between total signal intensity (M + U) and C9
status at each probe, using a mixed linear model as imple-
mented in OSCA. We identified 11 probes for which the
total signal intensity was significantly associated with C9
status (P < 1.1 × 10−7, Figure 4A). The majority of sig-
nificant probes (8 out of 11) were C9-mapping probes that
were also significant in the EWAS on -values (Figure 4A)
(Of note, three sites that showed diminished total intensities
in C9 carriers (right lower quadrant in Figure 4A) were lo-
cated in the immediate vicinity of the C9 repeat, presumably
because of frequent deletions that have been reported previ-
ously (40,41)). All intensity-associated C9-mapping probes
showed higher intensities in carriers of the expansion, indi-
cating more hybridization events at these probes in the car-
riers. We further found that the total OOB signal intensities
of nine probes were significantly associated with C9 status,
all being C9-mapping probes of whichmost were significant
in the OOB EWAS (Figure 4B). Finally, we found that these
results could not be explained by confounding signal satu-
ration effects (see Supplementary results for details).
The EPIC array shows similar cross-hybridization issues
We performed a replication analysis in two cohorts com-
prising 437 ALS patients that were profiled using the more
recent Illumina EPIC array (Supplementary Table S4). This
way we not only assess whether the cross-hybridization is-
sue is specific to our experiment, but also whether this is-
sue persists on the EPIC array. Out of the 18 significant
loci identified in the 450k data, 16 were present in the EPIC
data. Thirteen out of 16 loci replicated in the EPIC data at
a replication threshold (P = 0.05/16 = 0.003), and had a
consistent direction of effect (Figure 5 A and Supplemen-
tary Figure S17). The replicated loci included seven trans
probes that had a ≥14 bp match to the C9 repeat. Similarly,
four out of the nine probes that were significant in the 450k
OOB EWAS replicated in the EPIC data (Figure 5B). To
evaluate whether the EPIC array contains additional probes
that map to the C9 repeat, we mapped all EPIC probes to
the bisulfite-converted C9 repeat. We found that the EPIC
array contains 1127 C9-mapping probes (≥14bp match to
either unmethylated or methylated C9 repeat), of which 342
were specific to the EPIC array. DNA methylation at three
of these EPIC-specific probes were significantly associated
with carrier status (P < 0.05/1127). Finally, similar to the
450k array, we found that the significant probes from the
C9 EWAS in the EPIC data were enriched for probes with
longer matches to the C9 repeat (OR = 333, P = 2.3 ×
10−9).
DISCUSSION
In this paper, we report on hitherto undiscovered cross-
hybridization issues in Illumina DNA methylation arrays.
We discovered these issues in a large EWAS on the pres-
ence of the C9orf72 (C9) repeat expansion in ALS patients.
We provide strong evidence that the majority of the signif-
icant associations were spurious due to cross-hybridization
to the C9 repeat. Our findings highlight the extent to which
cross-reactivity can impact EWAS findings. Although pre-
vious studies have reported on cross-reactivity in Illumina
methylation arrays, only 2 out of 11 of the technical arte-
facts would have been removed based on existing guide-
lines. These findings are particularly relevant for epigenetic
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Figure 5. Comparison between test-statistics from the EWAS in the 450k cohort and test-statistics from the EWAS in the EPIC cohort. Probes flagged
as mapping to the C9 repeat (≥14 bp inexact match) and that were significant in the 450k EWAS are highlighted. (A) T-statistics from the EWAS in the
EPIC cohort (y-axis) compared with t-statistics from the EWAS in the 450k cohort (x-axis). (B) T-statistics from the EWAS on OOB -values in the EPIC
cohort (y-axis) compared with t-statistics from the EWAS on OOB -values in the 450k cohort (x-axis).
studies into diseases associated with repeat expansions and
other types of structural variation.More generally however,
we believe that the data-driven flag&consider approach we
employ in this study is relevant for any type of EWAS, since
we show that removing pre-defined sets of probes may miss
spurious associations.
We found several convergent lines of evidence that
strongly suggest that the majority of significant CpG-sites
were false positives due to cross-hybridization to the C9 re-
peat expansion. First, among the significant sites we found a
strong enrichment for probes with longer sequence matches
to the C9 repeat. This enrichment was present in both the
450k and EPIC array data. Second, we show that probes
predicted to cause fluorescent signal in the (unintended)
OOB color channel upon cross-hybridization to the C9 re-
peat indeed showed differential signal in these channels.
These findings indicate a novel use of the OOB signals, and
adds to previous studies that have shown that OOB signals
can provide valuable information (28,42). Third, the probes
that partially match the C9 repeat showed increased sig-
nal intensity levels in carriers of the expansion. This indi-
cates that these probesmeasure copy number differences be-
tween carriers and non-carriers, which supports the hypoth-
esis that these probes hybridize to the C9 repeat. Finally,
these probes were strongly correlated––albeit being spread
across the genome––and their direction of effect was con-
sistent with those found in the C9 repeat in previous studies
(43).
Spurious associations due to cross-hybridization have
long been recognized and various probe filtering ap-
proaches have been proposed to prevent them (9–12). The
most widely used method involves removing probes with a
≥47 bpmatch to an off-target region (10). In addition, it has
been proposed to remove all probes that overlap with repeti-
tive regions (11).More recently, a data-driven approach was
used to show that probes with off-target matches of 30 bp
or greater can lead to cross-reactive signals (12).
In this study, we made several novel observations that ex-
plain why the issues we discovered were not identified in any
of the aforementioned studies. Specifically, we show that ge-
netic variation should be taken into account when consider-
ing potential cross-hybridization issues, since these are not
covered by existing methods that map probes to the refer-
ence genome. This is especially relevant when the phenotype
being studied is associated with repeat expansions or other
types of structural variation, which have been implicated in
a substantial number of diseases (44). To exemplify this, we
show in Supplementary Tables S8 and 9 that similar issues
may be expected in diseases associated with other types of
repeat expansions. Although these findings are particularly
relevant for the cases described above, our findings also have
more general implications. First, our results suggest that
off-target sequence matches below the recently proposed
30 bp cutoff can lead to spurious associations (12). More-
over, we found that imperfect off-target matches (i.e. allow-
ing for mismatches/INDELs) can impact -value readouts.
In addition, inexact matching implicitly takes into account
that a probe may have an off-target match in some individ-
uals and not in others due to genetic variation (i.e. a probe
may onlymatch an off-target regionwhen an individual car-
ries a variant, which is not taken into account by mapping
to the reference genome).
An issue that emerges from this study is that off-target
sequence matches as low as 14 bp resulted in spurious as-
sociations. Excluding probes based on the aforementioned
cutoff would lead to the removal of practically all probes,
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and is therefore not a sensible strategy. Whether off-target
matches lead to detectable shifts in -values will ultimately
depend on several factors. These include the combination
of the number of off-target matches and the lengths of
thesematches.Whereas one or a few long off-targetmatches
may be sufficient for detectable cross-hybridization, a larger
number of short matches will generally be required to reach
detectable levels of off-target signal. Moreover, correlated
off-target signals will shift -values in the same direction
and are thus more likely to cause detectable shifts. In this re-
gard, we expect that many copies of an off-target sequence
are required before matches as small as those described
here (≥14 bp) will result in spurious associations. In ad-
dition, other factors may influence the likelihood of cross-
hybridization, such as the experimental washing protocols
and GC-content of the probe (45,46).
Due to this combination of contributing factors, it is not
straightforward to decide a priori which probes should be
excluded, and relying on a fixed threshold to exclude cross-
reactive probes can miss spurious associations. This conclu-
sion is supported by the fact that most of the cross-reactive
probes we discovered were not flagged as such in previous
studies. Moreover, we note that these phenomena, although
unintended, may represent biological signals of interest. We
therefore argue for a ‘flag and consider’ approach rather
than removing specified sets of probes beforehand, as previ-
ously suggested regarding probes that overlap with genetic
variation (47).
Several analytical checks used in this study can aid
in identifying probes that may be affected by cross-
hybridization. First, probes identified in an EWAS should
be checked for off-target sequence matches. In contrast
to previous studies, we recommend considering off-target
matches <30 bp and allowing for imperfect matches. In
addition, any known genetic variation associated with
the phenotype should be taken into account. We made
scripts to map significant probes to both reference and
non-reference sequences available in an R package (https:
//github.com/pjhop/DNAmCrosshyb). Second, we recom-
mend inspecting the results of an EWAS for the pres-
ence of various ’red flags’, which can point toward
cross-hybridization issues. These include (i) correlations
among (near-)significant probes; (ii) similar probe se-
quences among (near-)significant probes; (iii) absence of re-
gional effects at the target locus; (iv) association between
the phenotype of interest and total signal intensities and (v)
associations in type I OOB channels.
In the supplementary note we discuss these red flag sig-
nals in more detail, and show that varying sets of probes
map to other disease-associated repeat sequences. We note
that these red flags cannot conclusively confirm the pres-
ence or absence of cross-reactivity issues, however they do
provide a strong incentive for cautious interpretation and
follow-up of the results. Lastly, cross-reactivity is not the
only phenomenon that can lead to spurious associations,
most notably SNPs underlying the probe sequence also need
to be taken into account (12,47). Ideally, given array arte-
facts as described here, researchers need to replicate their
findings using a sequencing-based technique, even when
array results appear consistent across batches. For exam-
ple, bisulfite-pyrosequencing is a cost-effective method that
has been successfully used to validate array-based findings
(48,49).
To develop a full picture of the extent in which cross-
hybridization can impact EWASfindings, additional studies
will be needed. Due to the technical challenges involved in
determining the exact C9orf72 repeat length, we were un-
able to determine the relation between repeat length and
amount of off-target signal (29,50). Future studies investi-
gating this relation using long-read sequencing techniques
for example would be valuable. In addition, the impact of
factors such as GC-content and other experimental fac-
tors on cross-hybridization in DNA methylation arrays are
worth further exploring. Moreover, it is interesting to note
that the issues described here were limited to type I probes,
especially given that previous studies have suggested that
type II probes are more reliable than type I probes (51–
53). However, notably fewer type II probes showed sequence
overlap with the C9 repeat, and further studies would be re-
quired to establish whether type I and type II probes differ
in terms of cross-hybridization.
CONCLUSION
Illumina DNA methylation arrays provide a cost-effective
approach to interrogate genome-wide DNA methylation
levels in large samples and have proven to be a central
tool in epigenetic research. However, results obtained using
these arrays should be interpreted with caution as we em-
pirically show that cross-hybridization can result in many
false positive findings. Importantly, we found that excluding
probes a priori, based on published annotations of cross-
reactive probes, may fall short in preventing spurious asso-
ciations. In this paper, we report several checks to identify
said probes, and we expect that our approach will aid in pre-
venting spurious associations in DNA methylation studies.
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